Karel Ettler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karel Ettler has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
- Jarmila Celakovska
Department of Dermatology and Venereology Faculty Hospital and Medical Faculty of Charles University
10 shared publications Květuše Ettlerová
Department of Allergy and Clinical Immunology, Outpatient Clinic, Hradec Králové, Czech Republic
7 shared publications- Ctirad Andrys
Department of Clinical Immunology and Allergy, Charles University in Prague, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove
6 shared publications Josef Bukač
Department of Medical Biophysics Medical Faculty of Charles University Hradec Králové Czech Republic
6 shared publications- Lenka Borska
Department of Preventive Medicine, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, 500 03, Czech Republic, cuni.cz
6 shared publications Jan Krejsek
Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Department of Clinical Immunology and Allergy, Czech Republic
5 shared publications
Latest Publications
- 6 May 2024
- Published by Elsevier in Journal of Photochemistry and Photobiology A: Chemistry
- Vol. 454
Disposable indicator card for personal monitoring of solar exposure
- 6 May 2024
- Published by Elsevier in Journal of Photochemistry and Photobiology A: Chemistry
- Vol. 454
Disposable indicator card for personal monitoring of solar exposure
- Open Access
- 12 November 2021
- Published by Springer Nature in Dermatology and Therapy
- Vol. 11 (6) , 2123-2131
Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
Introduction Atopic dermatitis (AD), a predominantly type 2 inflammatory skin disease, affects approximately 2–5% of adults, with a high burden of disease. In moderate-to-severe AD, lesions can be extensive and pruritus intense with patients experiencing skin pain, sleep and mental health disturbances, and diminished quality of life (QoL). Methods The objective of this study was to evaluate the efficacy of dupilumab for the treatment of AD from the patients’ perspective using patient-reported outcome data from four clinical trials (CHRONOS, SOLO 1&2, and CAFÉ) in patients (N = 1553) receiving either the approved 300 mg q2w dupilumab with/without topical corticosteroids (TCS) dose or control (placebo or placebo + TCS). Patient Global Assessment of Disease Status (PGADS) was used to measure patients’ well-being and Patient Global Assessment of Treatment Effect (PGATE) was used to measure treatment efficacy. Patients were asked “Considering all the ways in which your eczema affects you, indicate how well you are doing” to assess their perception of well-being and “How would you rate the way your eczema responded to the study medication?” to assess their perception of treatment effect. Possible responses for both metrics included poor, fair, good, very good, and excellent. Results In all four studies, a significantly higher proportion of dupilumab-treated patients reported “Good”/”Very Good”/”Excellent” disease status from week 2 through study end versus control (CHRONOS, 52 weeks: 69.8% vs. 25.1%; SOLO 1&2, 16 weeks: 59.5% vs. 24.6%; CAFÉ, 16 weeks: 84.1% vs. 45.4%; all P < 0.0001), and significantly more dupilumab-treated patients reported “Good”/”Very Good”/”Excellent” treatment efficacy versus control (CHRONOS: 72.6% vs. 24.8%; SOLO 1&2: 65.0% vs. 21.1%; CAFÉ, 16 weeks: 85.0% vs. 36.1%; all P < 0.0001). Conclusion Adult patients with AD perceived that dupilumab with/without concomitant TCS was highly efficacious and improved overall disease status and well-being as early as week 2 and throughout treatment periods up to 1 year. Video Abstract (MP4 90521 kb)
- 12 November 2021
- Published by Springer Nature in Dermatology and Therapy
- Vol. 11 (6) , 2123-2131
Open AccessEfficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
Introduction Atopic dermatitis (AD), a predominantly type 2 inflammatory skin disease, affects approximately 2–5% of adults, with a high burden of disease. In moderate-to-severe AD, lesions can be extensive and pruritus intense with patients experiencing skin pain, sleep and mental health disturbances, and diminished quality of life (QoL). Methods The objective of this study was to evaluate the efficacy of dupilumab for the treatment of AD from the patients’ perspective using patient-reported outcome data from four clinical trials (CHRONOS, SOLO 1&2, and CAFÉ) in patients (N = 1553) receiving either the approved 300 mg q2w dupilumab with/without topical corticosteroids (TCS) dose or control (placebo or placebo + TCS). Patient Global Assessment of Disease Status (PGADS) was used to measure patients’ well-being and Patient Global Assessment of Treatment Effect (PGATE) was used to measure treatment efficacy. Patients were asked “Considering all the ways in which your eczema affects you, indicate how well you are doing” to assess their perception of well-being and “How would you rate the way your eczema responded to the study medication?” to assess their perception of treatment effect. Possible responses for both metrics included poor, fair, good, very good, and excellent. Results In all four studies, a significantly higher proportion of dupilumab-treated patients reported “Good”/”Very Good”/”Excellent” disease status from week 2 through study end versus control (CHRONOS, 52 weeks: 69.8% vs. 25.1%; SOLO 1&2, 16 weeks: 59.5% vs. 24.6%; CAFÉ, 16 weeks: 84.1% vs. 45.4%; all P < 0.0001), and significantly more dupilumab-treated patients reported “Good”/”Very Good”/”Excellent” treatment efficacy versus control (CHRONOS: 72.6% vs. 24.8%; SOLO 1&2: 65.0% vs. 21.1%; CAFÉ, 16 weeks: 85.0% vs. 36.1%; all P < 0.0001). Conclusion Adult patients with AD perceived that dupilumab with/without concomitant TCS was highly efficacious and improved overall disease status and well-being as early as week 2 and throughout treatment periods up to 1 year. Video Abstract (MP4 90521 kb)
Sensitisation to outdoor and indoor fungi in atopic dermatitis patients and the relation to the occurrence of food allergy to peanuts and walnuts
Summary: The aim of this study is the evaluation of the relation between the sensitisation to outdoor and indoor fungi and allergy to peanuts and walnuts in atopic dermatitis patients aged 14 years and older. The complete dermatological and allergological examinations were performed in all included patients; the occurrence of food allergy to peanuts and walnuts was recorded (specific IgE, skin prick test, history of allergic reaction) and the sensitisation to mixture of outdoor fungi and indoor fungi was also examined (skin prick test, specific IgE). The statistical evaluation of the relation between the sensitisation to outdoor and indoor fungi and the occurrence of food allergy to peanuts and walnuts was performed; 329 patients were included in the study, 110 men and 219 women, the average age 26.8 years. The sensitisation to outdoor fungi was recorded in 91 patients (28%), the sensitisation to indoor fungi was recorded in 61 patients (18.5%), the occurrence of food allergy to peanuts was confirmed in 90 (27%) patients and to walnuts in 121 (36.7%) patients. We confirmed, that patients suffering from sensitisation to outdoor fungi suffer significantly more from food allergy to peanuts and walnuts. The significant relation between the sensitisation to indoor fungi and food allergy to peanuts and walnuts was not confirmed.
Sensitisation to outdoor and indoor fungi in atopic dermatitis patients and the relation to the occurrence of food allergy to peanuts and walnuts
Summary: The aim of this study is the evaluation of the relation between the sensitisation to outdoor and indoor fungi and allergy to peanuts and walnuts in atopic dermatitis patients aged 14 years and older. The complete dermatological and allergological examinations were performed in all included patients; the occurrence of food allergy to peanuts and walnuts was recorded (specific IgE, skin prick test, history of allergic reaction) and the sensitisation to mixture of outdoor fungi and indoor fungi was also examined (skin prick test, specific IgE). The statistical evaluation of the relation between the sensitisation to outdoor and indoor fungi and the occurrence of food allergy to peanuts and walnuts was performed; 329 patients were included in the study, 110 men and 219 women, the average age 26.8 years. The sensitisation to outdoor fungi was recorded in 91 patients (28%), the sensitisation to indoor fungi was recorded in 61 patients (18.5%), the occurrence of food allergy to peanuts was confirmed in 90 (27%) patients and to walnuts in 121 (36.7%) patients. We confirmed, that patients suffering from sensitisation to outdoor fungi suffer significantly more from food allergy to peanuts and walnuts. The significant relation between the sensitisation to indoor fungi and food allergy to peanuts and walnuts was not confirmed.
- Open Access
- 28 June 2017
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (S4) , 12-30
Occupational skin diseases: actual state analysis of patient management pathways in 28 European countries
Background: Work‐related skin diseases (WSD) are caused or worsened by a professional activity. Occupational skin diseases (OSD) need to fulfil additional legal criteria which differ from country to country. OSD range amongst the five most frequently notified occupational diseases (musculoskeletal diseases, neurologic diseases, lung diseases, diseases of the sensory organs, skin diseases) in Europe.Objective: To retrieve information and compare the current state of national frameworks and pathways to manage patients with occupational skin disease with regard to prevention, diagnosis, treatment and rehabilitation in different European countries.Methods: A questionnaire‐based survey of the current situation regarding OSD patient management pathways was carried out with experts on occupational dermatology and/or occupational medicine from 28 European countries contributing to the European Cooperation in Science and Technology (COST) Action TD 1206 (StanDerm) (www.standerm.eu).Results: Besides a national health service or a statutory health insurance, most European member states implemented a second insurance scheme specifically geared at occupational diseases [insurance against occupational risks (synonyms: insurance against work accidents and occupational injuries; statutory social accident insurance)]. Legal standards for the assessment of occupationally triggered diseases with a genetic background differ between different countries, however, in most European member states recognition as OSD is possible. In one‐third of the countries UV light‐induced tumours can be recognized as OSD under specific conditions.Conclusion: OSD definitions vary between European countries and are not directly comparable, which hampers comparisons between statistics collected in different countries. Awareness of this fact and further efforts for standardization are necessary.
- 28 June 2017
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 31 (S4) , 12-30
Open AccessOccupational skin diseases: actual state analysis of patient management pathways in 28 European countries
Background: Work‐related skin diseases (WSD) are caused or worsened by a professional activity. Occupational skin diseases (OSD) need to fulfil additional legal criteria which differ from country to country. OSD range amongst the five most frequently notified occupational diseases (musculoskeletal diseases, neurologic diseases, lung diseases, diseases of the sensory organs, skin diseases) in Europe.Objective: To retrieve information and compare the current state of national frameworks and pathways to manage patients with occupational skin disease with regard to prevention, diagnosis, treatment and rehabilitation in different European countries.Methods: A questionnaire‐based survey of the current situation regarding OSD patient management pathways was carried out with experts on occupational dermatology and/or occupational medicine from 28 European countries contributing to the European Cooperation in Science and Technology (COST) Action TD 1206 (StanDerm) (www.standerm.eu).Results: Besides a national health service or a statutory health insurance, most European member states implemented a second insurance scheme specifically geared at occupational diseases [insurance against occupational risks (synonyms: insurance against work accidents and occupational injuries; statutory social accident insurance)]. Legal standards for the assessment of occupationally triggered diseases with a genetic background differ between different countries, however, in most European member states recognition as OSD is possible. In one‐third of the countries UV light‐induced tumours can be recognized as OSD under specific conditions.Conclusion: OSD definitions vary between European countries and are not directly comparable, which hampers comparisons between statistics collected in different countries. Awareness of this fact and further efforts for standardization are necessary.
- Top Cited Papers
- 1 June 2017
- Published by Elsevier in The Lancet
- Vol. 389 (10086) , 2287-2303
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
- 1 June 2017
- Published by Elsevier in The Lancet
- Vol. 389 (10086) , 2287-2303
Top Cited PapersLong-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
- Open Access
- 21 December 2016
- Published by Wiley in Journal of Immunology Research
- Vol. 2016, 1-8
Metabolic Syndrome and Selective Inflammatory Markers in Psoriatic Patients
The presented article studies the role of selected inflammatory and anti-inflammatory serum markers of psoriatic patients in the pathogenesis of metabolic syndrome (MS) and psoriasis. The study is based on the comparison between the group of psoriatic patients (74) and the control group (65). We found significantly higher BMI () and diastolic blood pressure () in the psoriatic patients. The values of waist circumference and BMI were significantly higher () in the male patients compared to the men in the control group. The analysis revealed significantly higher CRP (), Lp-PLA2 (), leptin (), and resistin () levels in the psoriatic patients. Significantly higher levels of CRP (), Lp-PLA2 (), leptin (), and resistin () were found in the patients with MS compared to the controls with MS. The level of adiponectin was significantly lower () in the patients with MS. Finally, we found significantly higher level of Lp-PLA2 () in the group of patients without MS compared to the controls without MS. In conclusion, observed inflammatory and anti-inflammatory markers (CRP, adiponectin, leptin, resistin, and Lp-PLA2) are involved in both pathogenesis of MS and pathogenesis of psoriasis. The level of Lp-PLA2 indicates the presence of subclinical atherosclerosis (cardiovascular risk) in psoriatic patients.- 21 December 2016
- Published by Wiley in Journal of Immunology Research
- Vol. 2016, 1-8
Open AccessMetabolic Syndrome and Selective Inflammatory Markers in Psoriatic Patients
The presented article studies the role of selected inflammatory and anti-inflammatory serum markers of psoriatic patients in the pathogenesis of metabolic syndrome (MS) and psoriasis. The study is based on the comparison between the group of psoriatic patients (74) and the control group (65). We found significantly higher BMI () and diastolic blood pressure () in the psoriatic patients. The values of waist circumference and BMI were significantly higher () in the male patients compared to the men in the control group. The analysis revealed significantly higher CRP (), Lp-PLA2 (), leptin (), and resistin () levels in the psoriatic patients. Significantly higher levels of CRP (), Lp-PLA2 (), leptin (), and resistin () were found in the patients with MS compared to the controls with MS. The level of adiponectin was significantly lower () in the patients with MS. Finally, we found significantly higher level of Lp-PLA2 () in the group of patients without MS compared to the controls without MS. In conclusion, observed inflammatory and anti-inflammatory markers (CRP, adiponectin, leptin, resistin, and Lp-PLA2) are involved in both pathogenesis of MS and pathogenesis of psoriasis. The level of Lp-PLA2 indicates the presence of subclinical atherosclerosis (cardiovascular risk) in psoriatic patients. - 17 March 2016
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (S3) , 46-51
The European Status Quo in legal recognition and patient‐care services of occupational skin cancer
Background: Skin cancer is the most common malignancy in Caucasian populations worldwide and ultraviolet radiation (UVR) is known for being the number one carcinogen. As, especially in outdoor workers, UVR is an inevitable carcinogen, the prevention and management of UVR‐related skin cancers in these at‐risk populations represent a collective challenge for dermatologists and healthcare policymakers likewise.Objective: To provide an overview on the current regulations on the acknowledgement and management of work‐related skin cancer in 11 European countries.Methods: Dermatologists from 11 countries networking within the EU Horizon 2020 COST Action TD1206 ‘StanDerm’ contributed to a standardized survey regarding current national regulations, implemented for the recognition, prevention and management as well as possible compensation regulations in their individual country of residence.Results: Ten of 11 participating countries in this survey reported the existence of an established programme available on certain occupational diseases; work‐related skin diseases were only specifically recognized in eight countries. Seven of 11 countries recognize cutaneous squamous cell carcinoma in outdoor workers as ‘occupational skin cancer’. Basal cell carcinoma (6 of 11), actinic keratosis (5 of 11), Bowen's disease (5 of 11) and malignant melanoma (5 of 11) are not as regularly approved as potentially ‘work‐induced’. Only a few of the countries included into this survey established a general documentation system (national registry) on occupational skin diseases. So far, representatives of only three countries of this survey referred to a specific established national programme for the prevention, management or compensation of occupational skin cancers acquired during work‐related UVR exposure.Conclusion: This survey highlights the need for mandatory regulations on the prevention, management and potential compensation of work‐related UV‐induced skin cancer across Europe. Against the background of a joint European domestic market, equal standards of occupational safety across Europe should include binding regulations for the protection and management of work‐related skin cancer. The design of a common regulation to meet the increasing incidence of skin cancers in outdoor workers should become part of the European agenda, ensuring equal working and living conditions in the member states.
- 17 March 2016
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (S3) , 46-51
The European Status Quo in legal recognition and patient‐care services of occupational skin cancer
Background: Skin cancer is the most common malignancy in Caucasian populations worldwide and ultraviolet radiation (UVR) is known for being the number one carcinogen. As, especially in outdoor workers, UVR is an inevitable carcinogen, the prevention and management of UVR‐related skin cancers in these at‐risk populations represent a collective challenge for dermatologists and healthcare policymakers likewise.Objective: To provide an overview on the current regulations on the acknowledgement and management of work‐related skin cancer in 11 European countries.Methods: Dermatologists from 11 countries networking within the EU Horizon 2020 COST Action TD1206 ‘StanDerm’ contributed to a standardized survey regarding current national regulations, implemented for the recognition, prevention and management as well as possible compensation regulations in their individual country of residence.Results: Ten of 11 participating countries in this survey reported the existence of an established programme available on certain occupational diseases; work‐related skin diseases were only specifically recognized in eight countries. Seven of 11 countries recognize cutaneous squamous cell carcinoma in outdoor workers as ‘occupational skin cancer’. Basal cell carcinoma (6 of 11), actinic keratosis (5 of 11), Bowen's disease (5 of 11) and malignant melanoma (5 of 11) are not as regularly approved as potentially ‘work‐induced’. Only a few of the countries included into this survey established a general documentation system (national registry) on occupational skin diseases. So far, representatives of only three countries of this survey referred to a specific established national programme for the prevention, management or compensation of occupational skin cancers acquired during work‐related UVR exposure.Conclusion: This survey highlights the need for mandatory regulations on the prevention, management and potential compensation of work‐related UV‐induced skin cancer across Europe. Against the background of a joint European domestic market, equal standards of occupational safety across Europe should include binding regulations for the protection and management of work‐related skin cancer. The design of a common regulation to meet the increasing incidence of skin cancers in outdoor workers should become part of the European agenda, ensuring equal working and living conditions in the member states.
- Open Access
- 9 July 2015
- Published by Charles University in Prague, Karolinum Press in Acta Medica (Hradec Kralove, Czech Republic)
- Vol. 58 (1) , 9-14
Egg Allergy in Adolescent and Adult Patient Suffering from Atopic Dermatitis – Association with Concomitant Allergic Diseases
Background: A few reports demonstrate the occurrence of egg allergy in adolescent and adult patients suffering from atopic dermatitis and the association of this allergy to other food and aeroallergens. Aims and Objectives: The aim of this study is to evaluate the occurrence of egg allergy in patients suffering from atopic dermatitis at the age 14 years and older and to evaluate the relationship between egg allergy or egg sensitisation and the sensitisation to dust, mites, feather, and animal dander. Materials and Methods: Complete dermatological and allergological examination was performed. These parameters were examined: food allergy and food sensitisation to egg white and yolk, to mites, animal dander (mixture), feather and dust. The statistical evaluation of the relations among egg allergy, egg sensitisation and sensitisation to mites, animal dander (mixture), feather and dust was performed. Two hundred and eighty eight patients were included in the study (90 men, 198 women, with the average age 25.2). Results and Conclusion: Egg allergy was recorded in 5% and egg sensitisation in 20% of patients; sensitisation to dust is recorded more often in patients with positive results in sIgE for egg white and/or yolk.
- 9 July 2015
- Published by Charles University in Prague, Karolinum Press in Acta Medica (Hradec Kralove, Czech Republic)
- Vol. 58 (1) , 9-14
Open AccessEgg Allergy in Adolescent and Adult Patient Suffering from Atopic Dermatitis – Association with Concomitant Allergic Diseases
Background: A few reports demonstrate the occurrence of egg allergy in adolescent and adult patients suffering from atopic dermatitis and the association of this allergy to other food and aeroallergens. Aims and Objectives: The aim of this study is to evaluate the occurrence of egg allergy in patients suffering from atopic dermatitis at the age 14 years and older and to evaluate the relationship between egg allergy or egg sensitisation and the sensitisation to dust, mites, feather, and animal dander. Materials and Methods: Complete dermatological and allergological examination was performed. These parameters were examined: food allergy and food sensitisation to egg white and yolk, to mites, animal dander (mixture), feather and dust. The statistical evaluation of the relations among egg allergy, egg sensitisation and sensitisation to mites, animal dander (mixture), feather and dust was performed. Two hundred and eighty eight patients were included in the study (90 men, 198 women, with the average age 25.2). Results and Conclusion: Egg allergy was recorded in 5% and egg sensitisation in 20% of patients; sensitisation to dust is recorded more often in patients with positive results in sIgE for egg white and/or yolk.
- 19 January 2015
- Published by Taylor & Francis in Food and Agricultural Immunology
- Vol. 26 (5) , 671-681
Food allergy, asthma bronchiale, and rhinitis in atopic dermatitis patients with total immunoglobulin E under and above 200 IU/ml
- 19 January 2015
- Published by Taylor & Francis in Food and Agricultural Immunology
- Vol. 26 (5) , 671-681
Food allergy, asthma bronchiale, and rhinitis in atopic dermatitis patients with total immunoglobulin E under and above 200 IU/ml
- 10 December 2014
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 29 (8) , 1500-1505
Sensitization to aeroallergens in atopic dermatitis patients: association with concomitant allergic diseases
Background: A few reports demonstrate the relationship between IgE sensitization to aeroallergens in atopic dermatitis (AD) patients and other allergic diseases and parameters.Objectives: The objective of this study was to evaluate, if there is a significant relationship between the sensitization to common aeroallergens in AD patients and the occurrence of asthma bronchiale, rhinitis and other atopic parameters.Methods: Sensitization to dust, mites, animal dander and bird feather was examined (skin prick test, specific IgE) and the relationship with the occurrence of asthma bronchiale, rhinitis, duration of AD, family history and onset of AD was evaluated.Results: Two hundred and eighty‐eight patients were examined – 90 men and 198 women. According to our results, IgE sensitization to animal dander, dust and mites may increase the risk of developing asthma or rhinitis. Persistent lesions of AD occur more often in patients with sensitization to animal dander, mites and dust. Patients with the sensitization to bird feather have the onset of AD more often above 5 years of age and in these patients, there is no relationship with the positive data about atopy in the family history.Conclusion: There is a greater likelihood of developing other allergic diseases in atopic dermatitis patients who suffer from sensitisation to animal dander, mites, and dust. Thus, prompt management of atopic dermatitis and allergy to inhallant allergens that develop in early infancy may be a successful method for preventing of atopic march.
- 10 December 2014
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 29 (8) , 1500-1505
Sensitization to aeroallergens in atopic dermatitis patients: association with concomitant allergic diseases
Background: A few reports demonstrate the relationship between IgE sensitization to aeroallergens in atopic dermatitis (AD) patients and other allergic diseases and parameters.Objectives: The objective of this study was to evaluate, if there is a significant relationship between the sensitization to common aeroallergens in AD patients and the occurrence of asthma bronchiale, rhinitis and other atopic parameters.Methods: Sensitization to dust, mites, animal dander and bird feather was examined (skin prick test, specific IgE) and the relationship with the occurrence of asthma bronchiale, rhinitis, duration of AD, family history and onset of AD was evaluated.Results: Two hundred and eighty‐eight patients were examined – 90 men and 198 women. According to our results, IgE sensitization to animal dander, dust and mites may increase the risk of developing asthma or rhinitis. Persistent lesions of AD occur more often in patients with sensitization to animal dander, mites and dust. Patients with the sensitization to bird feather have the onset of AD more often above 5 years of age and in these patients, there is no relationship with the positive data about atopy in the family history.Conclusion: There is a greater likelihood of developing other allergic diseases in atopic dermatitis patients who suffer from sensitisation to animal dander, mites, and dust. Thus, prompt management of atopic dermatitis and allergy to inhallant allergens that develop in early infancy may be a successful method for preventing of atopic march.